- Home
- SJT vs ACRS Comparison
SJT vs ACRS Comparison
Compare SJT & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SJT | ACRS |
|---|---|---|
| Founded | 1980 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 282.0M | 230.8M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | SJT | ACRS |
|---|---|---|
| Price | $5.78 | $3.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | 200.9K | ★ 1.3M |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $24,557.00 | ★ $15,742,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6.06 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.66 | $1.05 |
| 52 Week High | $7.22 | $3.57 |
Technical Indicators
Market Signals| Indicator | SJT | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 47.25 | 66.07 |
| Support Level | $5.82 | $3.12 |
| Resistance Level | $6.20 | $3.48 |
| Average True Range (ATR) | 0.24 | 0.22 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 54.74 | 79.80 |
Price Performance
Historical ComparisonAbout SJT San Juan Basin Royalty Trust
San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.